Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma.
Ceftriaxone-induced immune hemolytic anemia (CIHA) is the second most common cause of drug-induced hemolytic anemia. Prompt recognition of this drug reaction is essential because brisk hemolysis can be deadly. The extent to which ceftriaxone antibodies persist after CIHA is unknown; rechallenging patients who have experienced CIHA is not recommended. We report a case of CIHA in a neurooncology patient, which is the first to show anticeftriaxone antibodies with Rh specificity and persisted for 8 months after the drug reaction. These findings have implications for understanding the mechanism of CIHA.
Children's National Health System, Washington, District of Columbia.|Center for Cancer and Blood Disorders, Washington, District of Columbia.|Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.
L H
LH
Pecker
Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.|Department of Pathology, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.
A
A
Timsar
Children's National Health System, Washington, District of Columbia.
P P
PP
Pary
Diagnostic Laboratories, Blood Center of Wisconsin, Wisconsin.
G A
GA
Denomme
Children's National Health System, Washington, District of Columbia.
V R
VR
Criss
Children's National Health System, Washington, District of Columbia.|Center for Cancer and Blood Disorders, Washington, District of Columbia.|Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.|Department of Pathology, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.
N L C
NL
Luban
Children's National Health System, Washington, District of Columbia.|Center for Cancer and Blood Disorders, Washington, District of Columbia.|Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.
E I
EI
Hwang
Children's National Health System, Washington, District of Columbia.|Center for Cancer and Blood Disorders, Washington, District of Columbia.|Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.|Department of Pathology, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.
E C C
EC
Wong
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000906:Antibodies / Q000097:blood; D001932:Brain Neoplasms / Q000276:immunology*; D002443:Ceftriaxone / Q000009:adverse effects* / Q000276:immunology; D002675:Child, Preschool; D005260:Female; D005910:Glioma / Q000276:immunology*; D006801:Humans
D000900:Anti-Bacterial Agents; D000906:Antibodies; D002443:Ceftriaxone
anemias; blood bank; immune cytopenias; transfusion medicine